ArticleJournal of inflammation research2025
Serum IL-1β as a Novel Predictor of No-Reflow in STEMI Patients Undergoing Primary PCI.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Circulating NETosis Biomarkers in ST-Elevation Myocardial Infarction: Citrullinated Histone H3 Outperforms Cell-Free DNA and Nucleosomes.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite primary percutaneous coronary intervention (PPCI), over 10% of ST-segment elevation myocardial infarction (STEMI) patients develop the no-reflow phenomenon, characterized by microvascular inflammation. Novel forms of cell death, such as pyroptosis (IL-1β/GSDMD/Caspase-1) and ferroptosis (ACSL4/GPX4/PTGS2), may contribute to this inflammation by promoting cytokine release and leukocyte recruitment. However, the biomarker potential of these pathways in predicting no-reflow remains unclear. This study aimed to evaluate whether serum levels of these proteins could predict no-reflow and improve risk stratification. Patients and Methods: We enrolled 423 STEMI patients undergoing PPCI at two centers. No-reflow was defined as TIMI flow <3 following PPCI, excluding mechanical obstruction. Serum levels of pyroptosis- (IL-1β, GSDMD, Caspase-1) and ferroptosis-related proteins (ACSL4, GPX4, PTGS2) were measured using ELISA. Multivariable logistic regression identified independent predictors. The baseline model included age, sex, cardiovascular risk factors, and other baseline differences. Biomarker performance was assessed using ROC analysis, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: Of 423 patients, 81 (19.1%) developed no-reflow. The no-reflow group had significantly higher IL-1β [7.41 (5.55-10.80) vs 4.91 (3.70-6.71) pg/mL, P<0.001] and GSDMD levels [2.34 (1.75-3.48) vs 2.05 (1.64-2.71) ng/mL, P=0.017]. IL-1β was an independent predictor of no-reflow in both continuous [per SD increase: adjusted OR=2.260, 95% CI 1.723-2.966, P<0.001] and categorical analyses [highest vs lowest tertile: OR=6.484, 95% CI 2.864-14.679, P<0.001]. ROC analysis showed IL-1β alone had an AUC of 0.745 (95% CI: 0.686-0.804) for no-reflow prediction. Adding IL-1β to the baseline model improved discrimination (ΔAUC=0.091, P<0.001; NRI=0.627, P<0.001; IDI=0.109, P<0.001). Conclusion: Elevated serum IL-1β independently predicts no-reflow in STEMI patients, and its integration into the baseline model significantly enhances diagnostic performance, suggesting IL-1β as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.